

November 22, 2016
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Initiation of Patient Enrollment in the Phase 3 Clinical Trial
on the Patient-controlled Pain Management Drug “SyB P-1501”**

TOKYO, Japan, November 22, 2016 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, “Symbio”) announced today that the first patient has been enrolled in the Phase 3 clinical trial on “SyB P-1501,” – a drug for patient-controlled, short-term management of acute postoperative pain during hospitalization (“the Product”), which began in June 2016.

Symbio obtained the exclusive development and commercialization rights to the Product in Japan from The Medicines Company (Headquarters: New Jersey, U.S.) in October, 2015. The Product, launched in the U.S. and EU, was approved by the U.S. Food and Drug Administration (FDA) in April, 2015 and also approved by the European Medicines Agency (EMA) in November, 2015.

It is expected that the Product, non-invasive, needle-free, patient-controlled analgesia, will contribute to the quality of life of postoperative patients by mitigating the physical and mental burden they may suffer.

Symbio will timely proceed with this Phase 3 clinical trial as planned, aiming for the Product’s marketing and manufacturing approval in Japan in 2019 as Symbio’s second new drug following anti-cancer drug TREAKISYM®.

This event will not impact the Company’s current financial forecast.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare. The Company's mission is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in three critical therapeutic areas: serious infectious disease care, cardiovascular care and surgery and perioperative care.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.